| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Odafoamide (72-96 hours) showed cytotoxicity against liver cancer cells (SNU-475, SNU-449, C3A, IC50 values of 15 nM, 45 nM, and 5 nM, respectively) and non-small cell lung cancer cells (NSCLC) (NCI-H1944, NCI-H2228, NCI-H1755, NCI-H1563, NCI-H2110, and NCI-H1792, IC50 values of 2.3 nM, 0.21 nM, 8.2 nM, 2.5 nM, 1.1 nM, and 4.5 nM, respectively), and these cells had high levels of AKR1C3 protein and RNA expression [1]. Odafoamide showed strong anti-leukemic activity against 19 leukemia cell lines representing B-ALL, T-ALL and ETP-ALL (IC50 values of 60.3 nmol/L, 9.7 nmol/L and 31.5 nmol/L, respectively) [2].
|
|---|---|
| ln Vivo |
Odafoamide (1.25-5 mg/kg, intravenous injection, once a week for 2 weeks) inhibited tumor growth in HepG2 orthotopic xenograft mouse models[1]. Odafoamide (0.625-1.25 mg/kg, intravenous injection, once a week for 2 cycles; after a one-week break, 2 cycles of once-weekly administration were administered) inhibited tumor growth in H460 subcutaneous transplant mouse models[1]. Odafoamide (2.5 mg/kg or 5 mg/kg, intravenous injection, once a week for 4-5 cycles) inhibited tumor growth in (CRPC) VCaP, SNU-16 and A498 xenograft mouse models[1]. Odafoamide (1.25-5 mg/kg, intravenous injection, once a week for 3 weeks) inhibited tumor growth in PA1280, GA6201 and LU2505 xenograft mouse models[1]. Odafoamide (2.5 mg/kg, intraperitoneal injection, once a week for 3 weeks) caused significant and durable disease regression in a PDX mouse model of childhood acute lymphoblastic leukemia (ALL)[2].
|
| Animal Protocol |
Animal/Disease Models:HepG2 orthotopic xenograft (approximately 1 mm3 in diameter) female athymic nude mice (6 weeks; BALB/c-nu) model [1]
Doses: 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg Route of Administration: Intravenous injection, once a week for 2 weeks Experimental Results: Tumor growth was inhibited. The tumor growth inhibition rate (TGI) on day 34 was 52.4% in the 1.25 mg/kg group, 91.5% in the 2.5 mg/kg group, and 101.2% in the 5 mg/kg group. Animal/Disease Models:(CRPC) VCaP xenograft male BALB/c nude mouse model [1] Doses: 2.5 mg/kg, 5 mg/kg Route of Administration: Intravenous injection, once a week for 5 weeks Experimental Results: Inhibited tumor growth, with a growth inhibition rate of 148% at a dose of 5 mg/kg. When used in combination with abiraterone/prednisolone, the growth inhibition rate was further increased to 158%. Animal/Disease Models:PDX (female 20–25 g) NSG mouse pediatric ALL model [2] Doses: 2.5 mg/kg Route of Administration: Intraperitoneal injection once a week for 3 weeks Experimental Results: In All-8, ALL-27, ALL-29, ALL-30, ALL-31, ALL-28 and ALL-AKR1C3 models, combination therapy with nerabine significantly and persistently alleviated the disease and prolonged event-free survival in mice compared with either drug alone. |
| References |
|
| Molecular Formula |
C21H25N4O6P
|
|---|---|
| Molecular Weight |
460.42
|
| CAS # |
2097713-69-2
|
| Related CAS # |
(R)-Odafosfamide
|
| Appearance |
Light yellow to yellow oil
|
| SMILES |
C[C@@H](C1=CC(OC2=CC(C(N(C)C)=O)=CC=C2)=C(C=C1)[N+]([O-])=O)OP(N3CC3)(N4CC4)=O
|
| Synonyms |
(S)-OBI-3424; (S)-TH-3424; AST-3424
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~217.19 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.43 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1719 mL | 10.8596 mL | 21.7193 mL | |
| 5 mM | 0.4344 mL | 2.1719 mL | 4.3439 mL | |
| 10 mM | 0.2172 mL | 1.0860 mL | 2.1719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
